

Kenneth Aldape

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/57280/publications.pdf>

Version: 2024-02-01

107
papers

17,613
citations

81900

39
h-index

51608

86
g-index

112
all docs

112
docs citations

112
times ranked

20402
citing authors

#	ARTICLE	IF	CITATIONS
1	Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. <i>Neuro-Oncology</i> , 2023, 25, 339-350.	1.2	35
2	Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. <i>Neuro-Oncology</i> , 2022, 24, 571-581.	1.2	39
3	A molecularly integrated grade for meningioma. <i>Neuro-Oncology</i> , 2022, 24, 796-808.	1.2	83
4	DNA Methylation Profiling: An Emerging Paradigm for Cancer Diagnosis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2022, 17, 295-321.	22.4	83
5	The Alliance AMBUSH Trial: Rationale and Design. <i>Cancers</i> , 2022, 14, 414.	3.7	5
6	MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. <i>Cell Reports Methods</i> , 2022, 2, 100136.	2.9	8
7	High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13. <i>Acta Neuropathologica</i> , 2022, 143, 403-414.	7.7	13
8	Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology. <i>Acta Neuropathologica Communications</i> , 2022, 10, 19.	5.2	11
9	Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 547-574.	2.5	25
10	Diagnostic and Prognostic Implications of GNAS Inactivation in Sonic Hedgehog-Activated Medulloblastoma: Case Report with Comprehensive Molecular Profiling and Review of Literature. <i>JCO Precision Oncology</i> , 2022, 6, e2100403.	3.0	1
11	Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types. <i>Cancer Research</i> , 2022, 82, 2076-2083.	0.9	18
12	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2527-2535.	7.0	27
13	Astroblastomas exhibit radial glia stem cell lineages and differential expression of imprinted and X-inactivation escape genes. <i>Nature Communications</i> , 2022, 13, 2083.	12.8	3
14	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2022, 24, 1613-1646.	1.2	39
15	A T cell resilience model associated with response to immunotherapy in multiple tumor types. <i>Nature Medicine</i> , 2022, 28, 1421-1431.	30.7	23
16	DNA methylation analysis of glioblastomas harboring FGFR3-TACC3 fusions identifies a methylation subclass with better patient survival. <i>Acta Neuropathologica</i> , 2022, 144, 155-157.	7.7	10
17	Recurrent ACVR1 mutations in posterior fossa ependymoma. <i>Acta Neuropathologica</i> , 2022, 144, 373-376.	7.7	7
18	ETMR-06. Molecular and clinical characteristics of CNS tumors with BCOR(L1) fusion/internal tandem duplication. <i>Neuro-Oncology</i> , 2022, 24, i50-i50.	1.2	2

#	ARTICLE	IF	CITATIONS
19	RARE-15. Astroblastoma, <i>MN1</i> altered comprises two molecularly and clinically distinct subgroups defined by the fusion partners <i>BEND2</i> and <i>CXXC5</i> . <i>Neuro-Oncology</i> , 2022, 24, i12-i13.	1.2	1
20	DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncology. <i>Neuro-Oncology</i> , 2021, 23, S16-S29.	1.2	34
21	Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. <i>Neuro-Oncology</i> , 2021, 23, 506-507.	1.2	0
22	A novel <i>ATXN1-DUX4</i> fusion expands the spectrum of <i>CIC</i> -rearranged sarcoma™ of the CNS to include non- <i>CIC</i> alterations. <i>Acta Neuropathologica</i> , 2021, 141, 619-622.	7.7	16
23	Morphologic and Molecular Aspects of Glioblastomas. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 149-158.	1.7	3
24	Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History Study. <i>Neuro-Oncology Practice</i> , 2021, 8, 460-474.	1.6	12
25	Synthetic lethality-mediated precision oncology via the tumor transcriptome. <i>Cell</i> , 2021, 184, 2487-2502.e13.	28.9	60
26	TNF α secreted by glioma associated macrophages promotes endothelial activation and resistance against anti-angiogenic therapy. <i>Acta Neuropathologica Communications</i> , 2021, 9, 67.	5.2	28
27	Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. <i>Acta Neuropathologica</i> , 2021, 142, 179-189.	7.7	24
28	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC Tj ETQq000 rgBT/Overlock 10 Oncology, The, 2021, 22, 813-823.	10.7	132
29	MOMC-3. Hypermethylation and overexpression of HOX genes are poor prognosticators in Lower-Grade Glioma. <i>Neuro-Oncology Advances</i> , 2021, 3, ii4-ii4.	0.7	0
30	Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias. <i>JCO Precision Oncology</i> , 2021, 5, 1147-1150.	3.0	4
31	Recurrent fusions in <i>PLAGL1</i> define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. <i>Acta Neuropathologica</i> , 2021, 142, 827-839.	7.7	33
32	A clinically applicable integrative molecular classification of meningiomas. <i>Nature</i> , 2021, 597, 119-125.	27.8	180
33	Report of Canonical <i>BCR-ABL1</i> Fusion in Glioblastoma. <i>JCO Precision Oncology</i> , 2021, 5, 1348-1353.	3.0	3
34	Pediatric Gliomas Presenting with Gliomatosis-Like Spread, Lack of Contrast Enhancement, EGFR Mutation, and TERT Promoter Variants. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 1134-1136.	1.7	0
35	Immune cell deconvolution of bulk DNA methylation data reveals an association with methylation class, key somatic alterations, and cell state in glial/glioneuronal tumors. <i>Acta Neuropathologica Communications</i> , 2021, 9, 148.	5.2	9
36	A simple, high-throughput method of protein and label removal from extracellular vesicle samples. <i>Nanoscale</i> , 2021, 13, 3737-3745.	5.6	6

#	ARTICLE	IF	CITATIONS
37	Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. <i>Acta Neuropathologica</i> , 2021, 141, 281-290.	7.7	31
38	Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis. <i>Neuro-Oncology</i> , 2021, 23, 795-802.	1.2	3
39	Brief Report: Meningiomas in Patients with Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2021, , .	1.1	0
40	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , 2021, 39, 3839-3852.	1.6	93
41	INNV-27. AN INNOVATIVE VIRTUAL MULTI-INSTITUTIONAL, MULTIDISCIPLINARY NEURO-ONCOLOGY TUMOR BOARD: THE NIH-NOB EXPERIENCE DURING THE COVID-19 PANDEMIC. <i>Neuro-Oncology</i> , 2021, 23, vi111-vi111.	1.2	0
42	PATH-18. INTEGRATING TUMOR MICROENVIRONMENT WITH GENOMIC ABERRATIONS AND TUMOR CLASS IN ADULT GLIAL/GLIONEURONAL TUMORS BY DECONVOLUTION OF BULK METHYLATION DATA. <i>Neuro-Oncology</i> , 2021, 23, vi118-vi118.	1.2	0
43	DDRE-39. REPURPOSING CHEMOTHERAPIES AGAINST HIGH-RISK MENINGIOMAS WITH GUIDANCE BY METHYLATION PROFILES. <i>Neuro-Oncology</i> , 2021, 23, vi82-vi83.	1.2	0
44	EPCO-32. IDENTIFICATION OF PROGNOSTIC CHORDOMA SUBGROUPS USING DNA METHYLATION SIGNATURES IN TISSUE AND PLASMA. <i>Neuro-Oncology</i> , 2021, 23, vi9-vi9.	1.2	0
45	PATH-08. PROGNOSTIC IMPLICATIONS FROM LONG-TERM SURVIVORS (LTS) OF GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi116-vi116.	1.2	0
46	NCOG-34. A DESCRIPTIVE ANALYSIS OF GLIOMATOSIS CEREBRI CASES, COMPARED ACCORDING TO IDH STATUS. <i>Neuro-Oncology</i> , 2021, 23, vi159-vi159.	1.2	0
47	CTIM-32. IMMUNE CHECKPOINT INHIBITOR NIVOLUMAB IN PEOPLE WITH RECURRENT SELECT RARE CNS CANCERS: RESULTS OF INTERIM ANALYSIS IN A HEAVILY PRETREATED COHORT. <i>Neuro-Oncology</i> , 2021, 23, vi57-vi58.	1.2	2
48	PATH-46. DIAGNOSTIC IMPACT OF THE CNS TUMOR METHYLATION PROFILING IN A NEUROPATHOLOGY CONSULT PRACTICE. <i>Neuro-Oncology</i> , 2021, 23, vi125-vi126.	1.2	0
49	Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. <i>Cancers</i> , 2021, 13, 6092.	3.7	14
50	BRAF V600E mutant oligodendroglioma-like tumors with chromosomal instability in adolescents and young adults. <i>Brain Pathology</i> , 2020, 30, 515-523.	4.1	8
51	71. MGMT PROMOTER METHYLATION IS A PROGNOSTIC BIOMARKER IN EGFR MUTANT LUNG ADENOCARCINOMA WITH BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2020, 2, ii15-ii15.	0.7	1
52	Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa124.	0.7	5
53	MGMT Status as a Clinical Biomarker in Glioblastoma. <i>Trends in Cancer</i> , 2020, 6, 380-391.	7.4	131
54	NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors' Histone Mutated Midline Glioma Workshop Proceedings*. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa007.	0.7	4

#	ARTICLE	IF	CITATIONS
55	Minimalist approaches to cancer tissue-of-origin classification by DNA methylation. <i>Modern Pathology</i> , 2020, 33, 1874-1888.	5.5	18
56	Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes. <i>Nature Medicine</i> , 2020, 26, 1044-1047.	30.7	170
57	Diffuse intrinsic pontine glioma-like tumor with EZHIP expression and molecular features of PFA ependymoma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 37.	5.2	20
58	High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 101.	5.2	45
59	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. <i>Acta Neuropathologica</i> , 2020, 139, 603-608.	7.7	344
60	c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein. <i>Molecular Cancer Research</i> , 2020, 18, 774-786.	3.4	10
61	cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. <i>Brain Pathology</i> , 2020, 30, 844-856.	4.1	363
62	Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 601452.	2.8	1
63	Norrin mediates tumor-promoting and -suppressive effects in glioblastoma via Notch and Wnt. <i>Journal of Clinical Investigation</i> , 2020, 130, 3069-3086.	8.2	15
64	<i>In vitro</i> and <i>in vivo</i> identification of clinically approved drugs that modify ACE2 expression. <i>Molecular Systems Biology</i> , 2020, 16, e9628.	7.2	47
65	BSCI-26. COMPARATIVE METHYLATION PROFILING OF EGFR MUTANT LUNG ADENOCARCINOMA AND PAIRED BRAIN METASTASIS. <i>Neuro-Oncology Advances</i> , 2019, 1, i5-i6.	0.7	0
66	Highlights of the inaugural ten “the launch of Neuro-Oncology Advances. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz016.	0.7	0
67	Advances in multidisciplinary therapy for meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i18-i31.	1.2	102
68	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , 2019, 21, 901-910.	1.2	184
69	Reply to “Assembling the brain trust: the multidisciplinary imperative in neuro-oncology”. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 522-523.	27.6	0
70	Proteomic analysis of meningiomas reveals clinically distinct molecular patterns. <i>Neuro-Oncology</i> , 2019, 21, 1028-1038.	1.2	42
71	Needle in a haystack: identifying drivers of malignant transformation in neurofibromas. <i>Neuro-Oncology</i> , 2019, 21, 961-962.	1.2	0
72	Challenges to curing primary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 509-520.	27.6	540

#	ARTICLE	IF	CITATIONS
73	CIC protein instability contributes to tumorigenesis in glioblastoma. <i>Nature Communications</i> , 2019, 10, 661.	12.8	63
74	CMET-30. COMPREHENSIVE METHYLOME ANALYSIS OF EGFR-MUTANT PRIMARY LUNG ADENOCARCINOMA AND MATCHED BRAIN METASTASIS. <i>Neuro-Oncology</i> , 2019, 21, vi58-vi58.	1.2	0
75	CMET-32. DNA METHYLATION ALTERATIONS IN LUNG ADENOCARCINOMAS THAT DEVELOP BRAIN METASTASES. <i>Neuro-Oncology</i> , 2019, 21, vi58-vi58.	1.2	0
76	PATH-21. CLINICAL UTILITY OF DNA METHYLATION PROFILING FOR DIAGNOSIS OF CHALLENGING CENTRAL NERVOUS SYSTEM TUMORS: THE TORONTO EXPERIENCE. <i>Neuro-Oncology</i> , 2019, 21, vi147-vi147.	1.2	0
77	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019, 576, 112-120.	27.8	320
78	Imaging and diagnostic advances for intracranial meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i44-i61.	1.2	100
79	Molecular and translational advances in meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i4-i17.	1.2	92
80	5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma. <i>Acta Neuropathologica</i> , 2018, 135, 617-634.	7.7	15
81	A change at the helm of Neuro-Oncology. <i>Neuro-Oncology</i> , 2018, 20, 1-1.	1.2	62
82	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
83	The multiforme of glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 437-438.	1.2	3
84	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. <i>Journal of Clinical Investigation</i> , 2018, 129, 223-229.	8.2	130
85	CADD-49. IDENTIFICATION AND VALIDATION OF AZOLES AS HK2 INHIBITORS IN GLIOBLASTOMA <i>IN VITRO</i> AND <i>IN VIVO</i> . <i>Neuro-Oncology</i> , 2018, 20, vi282-vi282.	1.2	0
86	cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". <i>Acta Neuropathologica</i> , 2018, 136, 805-810.	7.7	599
87	A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 1039-1054.	1.7	105
88	World Health Organization 2016 Classification of Central Nervous System Tumors. <i>Neurologic Clinics</i> , 2018, 36, 439-447.	1.8	64
89	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	7.7	86
90	Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma. <i>Neuro-Oncology</i> , 2017, 19, 1503-1510.	1.2	18

#	ARTICLE	IF	CITATIONS
91	Molecular Signatures for Tumor Classification. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 881-891.	2.8	22
92	Precision histology: how deep learning is poised to revitalize histomorphology for personalized cancer care. <i>Npj Precision Oncology</i> , 2017, 1, 22.	5.4	127
93	Cribiform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. <i>Brain Pathology</i> , 2017, 27, 411-418.	4.1	58
94	IDH mutation testing in gliomas—where do we draw the line?. <i>Neuro-Oncology</i> , 2017, 19, 1568-1569.	1.2	2
95	Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients. <i>Neuro-Oncology</i> , 2016, 18, 1209-1218.	1.2	75
96	Bringing IDH into the Fold. <i>Cancer Cell</i> , 2016, 29, 139-140.	16.8	2
97	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	28.9	702
98	Surgically resected skull base meningiomas demonstrate a divergent postoperative recurrence pattern compared with non-skull base meningiomas. <i>Journal of Neurosurgery</i> , 2016, 125, 431-440.	1.6	49
99	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <i>Cancer Cell</i> , 2015, 27, 728-743.	16.8	933
100	Glioblastoma: pathology, molecular mechanisms and markers. <i>Acta Neuropathologica</i> , 2015, 129, 829-848.	7.7	503
101	Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. <i>Neuro-Oncology</i> , 2015, 17, 440-447.	1.2	102
102	Paediatric and adult glioblastoma: multifactorial (epi)genomic culprits emerge. <i>Nature Reviews Cancer</i> , 2014, 14, 92-107.	28.4	469
103	RESICstance Is Futile—But Not in Glioblastoma. <i>Cancer Cell</i> , 2014, 26, 156-157.	16.8	0
104	The Somatic Genomic Landscape of Glioblastoma. <i>Cell</i> , 2013, 155, 462-477.	28.9	3,979
105	Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas. <i>Cancer Immunology Research</i> , 2013, 1, 112-122.	3.4	192
106	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. <i>Cancer Cell</i> , 2012, 22, 425-437.	16.8	1,551
107	Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. <i>Cancer Cell</i> , 2010, 17, 510-522.	16.8	2,078